Ixabepilone: A new microtubule-targeting agent for breast cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 5, 2008, Pages 671-681

  Higa, Gerald M ^a   Abraham, Jame ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

tubulin; tubulin; tubulin; Dynamic instability; Ixabepilone; Microtubute; Polymerization; Taxane resistance

Indexed keywords

ALPHA TUBULIN; ANTHRACYCLINE DERIVATIVE; BETA TUBULIN; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPOTHILONE B; GEFITINIB; GLYCOPROTEIN P; IXABEPILONE; IXEMPRA; LAPATINIB; PACLITAXEL; PLACEBO; PROTEIN BCL 2; PROTEIN BCL XL; TAXANE DERIVATIVE; TRASTUZUMAB; VINCA ALKALOID; BRIDGED COMPOUND; EPOTHILONE DERIVATIVE; TAXANE; TAXOID; TUBULIN MODULATOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER INHIBITION; CANCER RELAPSE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HORMONAL THERAPY; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MICROTUBULE; MOLECULAR BIOLOGY; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; STOMACH DISEASE; STRUCTURE ANALYSIS; BREAST TUMOR; DRUG EFFECT; DRUG RESISTANCE; FEMALE; ULTRASTRUCTURE;

BREAST NEOPLASMS; BRIDGED COMPOUNDS; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEMALE; HUMANS; MICROTUBULES; TAXOIDS; TUBULIN MODULATORS;

EID: 45849114756     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.5.671     Document Type: Review

References (55)

1. Lee FYF, Borzilleri R, Fairchild CR et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. 7, 1429-1437 (2001).
2. McIntosh JR. The role of microtubules in chromosome movement. In: Microtubules. Hyams JS, Lloyd CW (Eds). Wiley-Liss, Inc., NY, USA 413-434 (1994).
3. Hayden JH, Bowser SS, Rieder CL. Kinetochores capture astral microtubules during chromosome attachment to the mitotic spindle: direct visualization in the live newt lung cells. J. Cell Biol. 11, 1039-1045 (1990).
4. Nogales E. Structural insights into microtubule function. Ann. Rev. Biochem. 69, 277-302 (2000).
5. Nogales E, Wolf SG, Downing DH. Structure of the αβ tubulin dimer by electron crystallography. Nature 391(6663), 199-203 (1998).
6. Kowalski RJ, Ter Haar E, Longley RE et al. Comparison of novel microtubule polymerizing agents, discodermolide and epothilone A/B with Taxol. Mol. Biol. Cell 6, 2137 (1995).
7. Giannakakou P, Gassio R, Nogales E et al. A common pharmacophore for epothilones and taxanes: a molecular basis for drug resistance confered by tubulin mutations in human cancer cells. Proc. Natl. Acad. Sci. USA 97, 2904-2909 (2000).
8. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 88, 2619-2628 (2000).
9. Donaldson KL, Goolsby G, Kiener PA Wahl AF. Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Diff. 5, 1041-1050 (1994).
10. Shaulsky G, Goldfinger N, Tosky MS, Levine AJ, Rotter V. Nuclear localization is essential for the activity of p53 protein. Oncogene 6, 2055-2065 (1991).
11. Thomas E, Tabernero J, Fornier M et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J. Clin. Oncol. 25, 3399-3406 (2007).
12. Perez EA, Lerzo G, Pivot X et al. Efficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 25, 3407-3414 (2007).
13. Roche H, Yelle L, Cognetti F et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J. Clin. Oncol. 25, 3415-3420 (2007).
14. Dcnduluri N, Low JA, Lee JJ et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J. Clin. Oncol. 25, 3421-3427 (2007).
15. Shimizu T, Yamamoto N, Yamada Y et al. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother. Pharmacol. (2007) (Epub ahead of print).
16. Abraham J, Agrawal M, Bakke S et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J. Clin. Oncol. 21, 1866-1873 (2003).
17. Mani S, McDaid HM, Grossman A et al. Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone analogue, ixabepilone. Ann. Oncol. 18, 190-195 (2007).
18. Seidman AD, Tiersten A, Hudis et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J. Clin. Oncol. 13, 2575-2581 (1995).
19. Trudeau ME, Eisenhauer EA, Higgins BP et al. Docetaxel in patients with metastatic breast cancer. A Phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J. Clin. Oncol. 14, 422-428 (1996).
20. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol. 25, 5210-5217 (2007).
21. Lee FY, Camuso A, Castenada C et al. Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma. J. Clin. Oncol. 24, 18(Suppl.), 12017 (2006) (Abstract).
22. Cussac AL, Baselga J, Manikhas G et al. Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer: preliminary efficacy and safety data. Proc. Am. Soc. Clin. Oncol. 23, (2005) (Abstract 586).
23. Takimoto CH, Liu PY, Lenz H et al. A Phase I pharmacokinetic (PK) study of the Epothilone B analogue, ixabepilone (BMS-247550) in patients (pts) with advanced malignancies and varying degrees of hepatic impairment. A SWOG Early Therapeutics Committee and NCI Organ Dysfunction Working Group Trial. Proc. Am. Soc. Clin. Oncol. 24 (2006) (Abstract 2004).
24. Hanahan D, Weinberg RA. Hallmarks of cancer. Cell 100, 57-70 (2000).
25. Lee S, Yang W, Lan KH et al. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res. 62, 5703-5710 (2002).
26. Moritz M, Braunfeld MB, Sedat JW, Alberts B, Agard DA. Microtubule nucleation by γ-tubulin-containing rings in the centrosome. Nature 378, 638-640 (1995).
27. Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D. The effect of loss of Brca1 on the sensitivity anticancer agents in p53-deficient cells. Int. J. Oncol. 22, 1169-1173 (2003).
28. Tassone P, Tagliaferri P, Perricelli A et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br. J. Cancer 88, 1285-1291 (2003).
29. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. 7, 542-547 (2001).
30. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res. 6, 127-134 (2000).
31. Xia W, Bisi J, Strum J et al. Regulation of survivin by HER2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res. 66, 1640-1647 (2006).
32. Dutertre S, Descamps S, Prigcnt C. On the role of aurora-A in centrosome function. Oncogene 21, 6175-6183 (2002).
33. Anand S, Penrhyn-Lowe S, Venkitaraman AR. Aurora-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to taxol. Cancer Cell 3, 51-62 (2003).
34. Sui M, Huang Y, Park BH, Davidson NE, Fan W. Estrogen receptor α mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res. 67, 5337-5344 (2007).
35. Martin M, Mackey J, Vogel C. Benefit from adjuvant taxanes and endrocrine responsiveness in breast cancer. Breast 16 (Suppl. 2), 127-131 (2007).
36. Razandi M, Pedram A, Levin ER. Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Mol. Endocrinol. 14, 1434-1447 (2000).
37. Hayes DF, Thor AD, Dressier LG et al. HER2 and response to paditaxel in node-positive breast cancer. N. Engl. J. Med. 357, 1496-1506 (2007).
38. Konecny GE, Thomssen C, Luck HJ et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J. Natl Cancer Inst. 96, 1141-1151 (2004).
39. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv. Exp. Med. Biol. 608, 1-22 (2007).
40. Lee FYF, Camuso A, Castenada S et al. Preclinical studies of ixabepilone (BMS-247550) demonstrate optimal antitumor activity against both chemotherapy-sensitive and -resistant tumor types. Proc. Am. Assoc. Cancer Res. 47 (2006) (Abstract 503).
41. Brooks TA, Minderman H, O'Loughlin KL et al. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol. Cancer Ther. 2, 119S-1205 (2003).
42. Chaudhary PM, Roninson III. Expression and activity of P-glycoprotein, a multidrog efflux pump, in human hematopoietic cells. Cell 66, 85-94 (1991).
43. Licht T, Pastan I, Gottesman M, Herrman F. P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells. Ann. Hematol. 69, 159-171 (1994).
44. Goncalves A, Braguer D, Kamath K et al. Resistance to Taxol in lung cancer cells associated with increased mictotubule dynamics. Proc. Natl Acad. Sci. USA 98, 11737-11742 (2001).
45. Jordan MA, Miller H, Ni L et al. The Pat-21 breast cancer model derived from a patient with primary Taxol resistance recapitulates the phenotype of its origin, has altered β-tubulin expression and is sensitive to ixabepilone. Proc. Am. Assoc. Cancer Res. 47 (2006) (Abstract LB-280).
46. Fujimoto-Ouchi K, Sekiguchi F, More I. Preclinical study of continuous administration trastuzumab as combination therapy after disease progresses with trastuzumab monotherapy. Proc. Am. Assoc. Cancer Res. 46 (2005) (Abstract 5062).
47. Yamaguchi H, Paranawithana SR, Lee MW, Huang Z, Bhalla KN, Wang HG. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res. 62, 466-471 (2002).
48. Huang Y, Ray S, Reed JC et al. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res. Treat. 42, 73-81 (1997).
49. MacKeigan JP, Collins TS, Ting JP. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J. Biol. Chem. 275, 38953-38956 (2000).
50. Nicholson KM, Anderson NG. The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal. 14, 381-395 (2002).
51. Fujino L, Bali P, Wittmann S et al. Histone deactylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol. Cancer Ther. 2, 971-984 (2003).
52. Lee FYF, Vite G, Borzilleri R et al. Preclinical pharmacology of the epothilone B analog BMS-247550-an epothilone analog possessing potent activity against paclitaxel-sensitive and -resistant human tumors. Clin. Cancer Res. 6 (2000) (Abstract S4580).
53. Valero V, Jones SE, Von Hoff DD et al. A Phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J. Clin. Oncol. 16, 3362-3368 (1998).
54. Blum JL, Jones SE, Buzdar AU et al. Multicenter Phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. 17, 485-493 (1999).
55. Jones SE, Erban J, Overmoyer B et al. Randomized Phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J. Clin. Oncol. 23, 5542-5551 (2005).